seekingalpha.com
Medexus Pharmaceuticals Inc. (MDP:CA) Q3 2026 Earnings Call Transcript
Medexus Pharmaceuticals Inc. (MDP:CA) Q3 2026 Earnings Call Transcript
MEDXFMEDXFOTC
Loading
Latest News
Loading news...
newsfilecorp.com
Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Management to host conference call at 8:00 AM Eastern time on Thursday, February 12, 2026 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 11, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's third fiscal quarter ended December 31, 2025 (the company's fiscal Q3 2026). All dollar amounts in this press release are in US dollars unless specified otherwise.
newsfilecorp.com
Medexus Schedules Third Fiscal Quarter 2026 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 3, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 12, 2026 to discuss Medexus's results for its third fiscal quarter ended December 31, 2025. Medexus expects to file its financial statements and MD&A after markets close on February 11, 2026.
newsfilecorp.com
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 20, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock Exchange has accepted Medexus's notice of intention to make a normal course issuer bid, or NCIB, for its common shares (TSX: MDP). Under the NCIB, Medexus may purchase for cancellation up to 2,983,650 common shares, representing approximately 10% of the public float as defined under TSX rules.
newsfilecorp.com
Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today entered into a new senior secured credit agreement with National Bank of Canada as administrative agent. The credit agreement provides for a US$21.0 million term loan facility and a US$5.0 million revolving loan facility.
seekingalpha.com
Medexus Pharmaceuticals Inc. (MDP:CA) Q2 2026 Earnings Call Transcript
Medexus Pharmaceuticals Inc. ( MDP:CA ) Q2 2026 Earnings Call November 13, 2025 8:00 AM EST Company Participants Kenneth d'Entremont - CEO & Director Brendon Bushman - Chief Financial Officer Conference Call Participants Victoria Rutherford - Adelaide Capital Andre Uddin - Research Capital Corporation, Research Division Michael Freeman - Raymond James Ltd., Research Division Scott Henry - Alliance Global Partners, Research Division Gireesh Seesankar - Bloom Burton & Co., Research Division Presentation Operator Good morning, everyone, and welcome to the Medexus Pharmaceuticals Second Quarter 2026 Conference Call.
newsfilecorp.com
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Management to host conference call at 8:00 AM Eastern time on Thursday, November 13, 2025 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 12, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's second fiscal quarter ended September 30, 2025 (the company's fiscal Q2 2026). All dollar amounts in this press release are in United States dollars unless specified otherwise.
newsfilecorp.com
Medexus Schedules Second Fiscal Quarter 2026 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November 13, 2025 to discuss Medexus's results for its second fiscal quarter ended September 30, 2025. Medexus expects to file its financial statements and MD&A after markets close on November 12, 2025.
newsfilecorp.com
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 25, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 12, 2025 as directors through the next annual meeting.
seekingalpha.com
Medexus Pharmaceuticals Inc. (MDP:CA) Shareholder/Analyst Call Prepared Remarks Transcript
Medexus Pharmaceuticals Inc. (TSX:MDP:CA ) Shareholder/Analyst Call September 25, 2025 10:00 AM EDT Company Participants Michael Mueller Ian Wildgoose Brown - General Counsel & Corporate Secretary Brendon Bushman - Chief Financial Officer Kenneth d'Entremont - CEO & Director Presentation Operator Hello, and welcome to the Annual Meeting of Shareholders of Medexus Pharmaceuticals Inc. Please note that today's meeting is being recorded. If you participate in today's meeting and disclose personal information, you will be deemed to consent to the recording, transfer and use of the same.
seekingalpha.com
Medexus Pharmaceuticals Inc. (MEDXF) Q1 2026 Earnings Call Transcript
Medexus Pharmaceuticals Inc. (OTCQX:MEDXF) Q1 2026 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Brendon Buschman - Chief Financial Officer Kenneth d'Entremont - CEO & Director Victoria Rutherford - Corporate Participant Conference Call Participants Andre Uddin - Research Capital Corporation, Research Division Gireesh Seesankar - Bloom Burton & Co., Research Division Michael W. Freeman - Raymond James & Associates, Inc., Research Division Scott Robert Henry - Alliance Global Partners, Research Division Operator Good morning, everyone, and welcome to the Medexus Pharmaceuticals First Quarter 2026 Conference Call.
newsfilecorp.com
Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection
Fiscal Q1 2026 net revenue of $24.6 million, net income of $0.5 million, operating income of $0.9 million, and Adjusted EBITDA* of $3.4 million $3.0 million of product-level net revenue from GRAFAPEX in fiscal Q1 2026, relative to $3.0 million of personnel and infrastructure investments, further supporting Medexus's confidence in the product's potential Management to host conference call at 8:00 AM Eastern time on Wednesday, August 13, 2025 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 12, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's first fiscal quarter ended June 30, 2025 (the company's fiscal Q1 2026). All dollar amounts in this press release are in United States dollars unless specified otherwise.
newsfilecorp.com
Medexus Schedules First Fiscal Quarter 2026 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, August 13, 2025 to discuss Medexus's results for its first fiscal quarter ended June 30, 2025. Medexus expects to file its financial statements and MD&A after markets close on August 12, 2025.
newsfilecorp.com
GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS's Fiscal Year 2026
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the US Centers for Medicare & Medicaid Services (CMS) has approved New Technology Add-On Payment (NTAP) reimbursement for eligible cases involving the use of GRAFAPEX™ (treosulfan) for Injection for CMS's fiscal year 2026, which runs from October 1, 2025 to September 30, 2026.* The NTAP program is designed to provide temporary supplemental reimbursement to institutions that use designated new higher-cost medical technologies in the first few years after introduction to the market.
seekingalpha.com
Medexus Pharmaceuticals Inc. (MEDXF) Q4 2025 Earnings Call Transcript
Medexus Pharmaceuticals Inc. (OTCQX:MEDXF) Q4 2025 Earnings Conference Call June 26, 2025 8:00 AM ET Company Participants Brendon Buschman - Chief Financial Officer Kenneth d'Entremont - CEO & Director Conference Call Participants Andre Uddin - Research Capital Corporation, Research Division David C. Martin - Bloom Burton & Co., Research Division Michael W.
newsfilecorp.com
Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States
Fiscal year 2025 revenue of $108.3 million, record net income of $2.2 million, operating income of $8.2 million, and record Adjusted EBITDA* of $20.2 million US commercial launch of GRAFAPEX™ executed in February 2025, following swiftly on the FDA's approval in January 2025, with initial indicators supporting Medexus's confidence in the product's potential Management to host conference call at 8:00 AM Eastern time on Thursday, June 26, 2025 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's fourth fiscal quarter and fiscal year ended March 31, 2025 (the company's fiscal Q4 2025 and fiscal year 2025). All dollar amounts in this press release are in United States dollars unless specified otherwise.
newsfilecorp.com
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 26, 2025 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2025. Medexus expects to file its financial statements and MD&A after markets close on June 25, 2025.
newsfilecorp.com
Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed a listing agreement with the provincial government of Quebec for Trecondyv® (treosulfan for injection). The Public Prescription Drug Insurance Plan of the Régie de l'Assurance Maladie du Québec, or RAMQ, will now reimburse eligible claims made for Trecondyv®.
newsfilecorp.com
Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 7, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to provide a business update on the progress of the commercial launch of GRAFAPEX™ (treosulfan) for Injection in the United States and announce company management's participation in two upcoming investor conferences. Medexus has seen an encouraging market response to GRAFAPEX™ in the weeks since the February 24 commercial launch of the product.
newsfilecorp.com
Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp.
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 14, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed an agreement with NX Development Corp., the licensor of Medexus's rights to Gleolan® in the United States, to terminate the license, supply, and distribution agreement between the parties and return responsibility for Gleolan® in the United States to NXDC as of a date no later than March 31, 2025. Under the terms of the termination agreement, Medexus will receive an agreed per-unit amount on units of Gleolan® sold by NXDC through June 30, 2025 that approximates the product's past per-unit contribution to Medexus during the term of the now-terminated agreement, which will reduce Medexus's royalty payment to NXDC for fiscal year 2025, due in June 2025.